$Assembly Biosciences Inc.(ASMB)$Infectious disease has definitely been on everyone’s radar for the past couple of years. And while corona made the headlines, it’s hardly the only serious pathogen out there. Hepatitis B virus (HBV) has long been known as a serious public health matter. The virus causes chronic, progressive, and severe liver disease, and while vaccines can prevent infection and transmission, there are few fully effective treatments available for patients suffering with the disease. Assembly Biosciences aims to change that situation.The company has an active research pipeline, featuring no fewer than three core inhibitor drug candidates. This is a new class of drugs, designed to interfere with the virus life cycle by blocking the virus